文献类型：期刊文献

中文题名：加味小白虎汤治疗对肺胃燥热型2型糖尿病胰岛素抵抗和胰岛β细胞功能的影响

英文题名：Effects of modified Xiaobaihu decoction on insulin resistance and islet beta cell function in type 2 diabetes mellitus with pulmonary and gastric desiccating fever

作者：康学东[1];高攀[2,3];吕娟[2];杨维杰[1];余臣祖[2]

第一作者：康学东

机构：[1]甘肃中医药大学附属医院,甘肃兰州730020;[2]甘肃中医药大学,甘肃兰州730000;[3]榆林市第一医院,陕西榆林718000

第一机构：甘肃中医药大学第二附属医院

年份：2020

卷号：12

期号：21

起止页码：57

中文期刊名：中医临床研究

外文期刊名：Clinical Journal Of Chinese Medicine

基金：2017年甘肃省中医药管理局科研项目(编号:GZK-2017-13)。

语种：中文

中文关键词：加味小白虎汤;2型糖尿病;肺胃燥热;胰岛功能

外文关键词：Modified Xiaobaihu decoction;Type 2 diabetes;Pulmonary and gastric desiccating fever;Islet function

摘要：目的:探究分析加味小白虎汤对2型糖尿病(Type 2 Diabetes Mellitus,T2DM)肺胃燥热型的临床疗效,以获得高级别的"证据"说明经方治疗2型糖尿病的疗效.方法:本临床试验选取甘肃中医药大学附属医院内分泌科2017年1月-2017年12月初发或初治的2型糖尿病患者中肺胃热型者为研究对象,随机分成两组,对照组采用西医糖尿病标准治疗,治疗组在对照组干预方案基础上采用加味小白虎汤治疗;两组疗程均为12周.观察两组患者治疗前后的空腹血糖(Glucose,GLU),餐后2 h血糖(2 h Postprandial Blood Glucose,2 hPG)和糖化血红蛋白(Hemoglobin A1c,HbA1c),血脂检测指标为三酰甘油(Triglyceride,TG)、胆固醇(Total Cholesterol,TC)、低密度脂蛋白胆固醇(Low-Density Lipoprotein Cholesterol,LDL-C)及高密度脂蛋白胆固醇(High-Density Lipoprotein Cholesterol,HDL-C).胰岛素敏感性指数(Insulin Sensitivity Index,ISI),胰岛素抵抗性指数(Homeostasis Model Assessment-Insulin Resistance,HOMA-IR),观察胰岛素分泌指数(Homeostatic Model Assessment-β,HOMA-β)等变化情况.结果:①两组组内比较:治疗后,GLU,2 hPG,糖化血红蛋白,血脂和胰岛素抵抗指数均显著低于治疗前,胰岛素敏感指数和干预前相比有所改善,差异有统计学意义(P<0.05);②组间比较:治疗组FPG,2 hPG和HbA1c降低明显高于对照组,差异有统计学意义(P<0.05).治疗组TG降低程度组间比对照组更显著,差异有统计学意义(P<0.01).治疗组HOMA-IR的下降程度明显高于对照组,ISI的程度比对照组更显著,差异有统计学意义(P<0.05).安全性:两组治疗期间均无明显不良反应.结论:加味小白虎汤针对2型糖尿病早期肺胃燥热型辨证施治,可以降低血糖、血脂同时显著提高机体胰岛素敏感性,在临床上值得推广应用.
Objective:To explore and analyze the clinical effect of modified Xiaobaihu decoction(加味小白虎汤)on type 2 diabetes mellitus(T2DM)patients with pulmonary and gastric desiccating fever,so as to obtain high-level"evidence"of the efficacy of Jingfang in the treatment of type 2 diabetes mellitus.Methods:In this clinical trial,patients with pulmonary and gastric fever who were diagnosed or initially treated in the department of endocrinology of Affiliated Hospital of Gansu University of Chinese Medicine from January 2017 to early December 2017 were selected as research subjects.They were randomly divided into two groups.Two groups of treatment was for 12 weeks.The fasting blood glucose(GLU),2 h blood glucose after a meal(2 hPG)and glycosylated hemoglobin(HbA1c),blood lipid(TC,TG,HDL-C,LDL-C),insulin sensitivity index(ISI),insulin resistance index(HOMA IR),insulin secretion index(HOMA-β)and so on of two groups of patients before and after treatment were observed.Results:1.Intra-group comparison:after treatment,GLU,2 hPG,HbA1c,lipid profile and insulin resistance index were significantly lower than those before treatment,and insulin sensitivity index was improved compared with that before intervention,which was with statistically significant difference(P<0.05);2.Comparison between the two groups:the reduction of FPG,2 hPG and HbA1c in the treatment group was significantly higher than that in the control group,which was with statistically significant differences(P<0.05).TG reduction in the treatment group was more significant than that in the control group,and the difference was statistically significant(P<0.01).The degree of HOMA-IR in the treatment group was significantly higher than that in the control group,and the degree of ISI was more significant than that in the control group,which was with statistically significant differences(P<0.05).3.Security:No significant adverse reactions occurred during treatment in both groups.Conclusion:Modified Xiaobaihu is targeted at the early stage of type 2 diabetes,which can reduce blood sugar and lipids and significantly improve the body's insulin sensitivity.Therefore,it is worthy of promotion and application in clinical practice.